PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
AboutPricing
Drug ReportsOctocrylene
Octocrylene
Anthelios, Capital Soleil (octocrylene) is a small molecule pharmaceutical. Octocrylene was first approved as Anthelios sx on 2006-07-21.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
Combinations
Anthelios, Anthelios sx, Capital soleil
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Avobenzone
+
Ecamsule
+
Octocrylene
+
Titanium dioxide
Tradename
Company
Number
Date
Products
ANTHELIOS 20L'OréalN-021471 OTC2006-10-05
1 products, RLD, RS
ANTHELIOS 40L'OréalN-022009 OTC2008-03-31
2 products, RLD, RS
Avobenzone
+
Ecamsule
+
Octocrylene
Tradename
Company
Number
Date
Products
ANTHELIOS SXL'OréalN-021502 OTC2006-07-21
1 products, RLD, RS
CAPITAL SOLEIL 15L'OréalN-021501 OTC2006-10-02
1 products, RLD, RS
Labels
FDA
EMA
Brand Name
Status
Last Update
belif the true cream aqua bomb sunscreen broad spectrum spf 50OTC monograph final2023-08-08
la roche posay anthelios sunscreen spf 60 ultra lightC2002632023-12-21
la roche posay face body anthelios spf 60 melt in milk fast absorbing, velvety finish for all skin types with cell-oc shield xlC2002632024-02-29
la roche posay laboratoire dermatologiqueC2002632023-12-31
la roche posay laboratoire dermatologique anthelios 30 cooling water broad spectrum spf 30 sunscreenC2002632023-12-31
la roche posay laboratoire dermatologique anthelios 50 daily antiaging primer with sunscreenC2002632023-12-31
la roche posay laboratoire dermatologique anthelios 50 mineral daily tone correcting primer broad spectrum spf 50 sunscreenC2002632024-01-01
la roche posay laboratoire dermatologique anthelios 50 mineral ultra light broad spectrum spf 50 sunscreenC2002632023-12-13
la roche posay laboratoire dermatologique anthelios 50 tinted mineral face broad spectrum spf 50 sunscreenC2002632024-01-15
la roche posay laboratoire dermatologique anthelios 50 tinted mineral sunscreen broad spectrum spf 50C2002632024-01-15
Show 25 more
Indications
FDA
EMA
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
5 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
MelanosisD008548HP_0001480L81.111
SunburnD013471EFO_0003958L5511
Indications Phases 3
No data
Indications Phases 2
No data
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Skin neoplasmsD012878EFO_0004198C4411
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
DermatitisD003872HP_0011123L30.911
Photoallergic dermatitisD01745411
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameOctocrylene
INNoctocrilene
Description
Octocrylene is a diarylmethane.
Classification
Small molecule
Drug class
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
CCCCC(CC)COC(=O)C(C#N)=C(c1ccccc1)c1ccccc1
Identifiers
PDB
CAS-ID6197-30-4
RxCUI
ChEMBL IDCHEMBL1201147
ChEBI ID
PubChem CID22571
DrugBank
UNII ID5A68WGF6WM (ChemIDplus, GSRS)
Target
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 430 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
133,573 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use